Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 2/20 | 0.73 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.73 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.73 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.73 |
| ▸ | FERMT2 | Q96AC1 | 1/20 | 0.65 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5364135 | 0.87 | MEN1 (0.57) | HTR1AADRA1DADRA1AADRA1BFERMT2 | |
| SCHEMBL4142709 | 0.86 | HTR1A (0.80) | HTR1AADRA1DADRA1AADRA1BFERMT2 | |
| SCHEMBL17994860 | 0.83 | HTR1A (0.79) | HTR1AADRA1DADRA1AADRA1BFERMT2 | |
| SCHEMBL16916968 | 0.82 | HTR1A (0.82) | HTR1AADRA1DADRA1AADRA1BFERMT2 | |
| SCHEMBL30307405 | 0.82 | HTR1A (0.82) | HTR1AADRA1DADRA1AADRA1BFERMT2 | |
| SCHEMBL18631820 | 0.81 | HTR1A (0.83) | HTR1AADRA1DADRA1AADRA1BFERMT2 | |
| SCHEMBL12212945 | 0.81 | HTR1A (0.67) | HTR1AADRA1DADRA1AADRA1BFERMT2 | |
| SCHEMBL15923360 | 0.80 | HTR1A (0.85) | HTR1AADRA1DADRA1AADRA1BFERMT2 | |
| SCHEMBL16585552 | 0.80 | HTR1A (0.61) | HTR1AADRA1DADRA1AADRA1BFERMT2 | |
| SCHEMBL31197364 | 0.80 | HTR1A (0.85) | HTR1AADRA1DADRA1AADRA1BFERMT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190076541-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Theraprutics, Inc. (US) | 2019-03-14 | — | — | US | disclosed |
| US-9951044-B2 | Quinazoline derivatives and their use as DNA methyltransferase inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2018-04-24 | — | — | US | disclosed |
| US-20140151548-A1 | MATRIX FOR MALDI MASS SPECTROMETRY AND MALDIMASS SPECTROMETRY METHOD | KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) | 2014-06-05 | — | — | US | disclosed |
| US-20140151548-A1 | MATRIX FOR MALDI MASS SPECTROMETRY AND MALDIMASS SPECTROMETRY METHOD | KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) | 2014-06-05 | — | — | US | disclosed |
| US-8546405-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2013-10-01 | — | — | US | disclosed |
| US-8541424-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2013-09-24 | — | — | US | disclosed |
| US-20110251210-A1 | MODIFIED CHLOROQUINES WITH SINGLE RING MOIETY OR FUSED RING MOIETY | PORTLAND STATE UNIVERSITY (US) | 2011-10-13 | — | — | US | disclosed |
| US-20100168138-A1 | Anti-Viral Compounds | ABBOTT LABORATORIES (US) | 2010-07-01 | — | — | US | disclosed |
| US-20100160355-A1 | Anti-Viral Compounds | ABBOTT LABORATORIES (US) | 2010-06-24 | — | — | US | disclosed |
| EP-1509497-A1 | CALCIUM RECEPTOR MODULATING ARYLALKYLAMINES | Amgen Inc. (US) | 2005-03-02 | — | — | EP | disclosed |
| WO-2003099776-A1 | CALCIUM RECEPTOR MODULATING ARYLALKYLAMINES | AMGEN INC. (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168138-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | HTR1A 4719/4885ADRA1D 4642/4885ADRA1A 4479/4885 |
| US-20110251210-A1 | MODIFIED CHLOROQUINES WITH SINGLE RING MOIETY OR FUSED RING MOIETY | QARS1, MAVS, QDPR | HTR1A 4166/4885ADRA1D 4476/4885ADRA1A 3966/4885 |
| US-20100160355-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | HTR1A 4719/4885ADRA1D 4642/4885ADRA1A 4479/4885 |
| US-20190076541-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | CRBN, MDM2, STUB1 | HTR1A 2096/4885ADRA1D 3540/4885ADRA1A 3386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.